CHU de Nice - Hôpital de l'Archet
Nice, Alpes-Maritimes, 06200, France
NCT Number: NCT06644157
Melasma is a frequently acquired hyperpigmentary disorder affecting up to 30% of child-bearing women in some populations. Melasma is still often called chloasma or the pregnancy mask and is considered as the main consequence of female hormone stimulation on a predisposed genetic background but only 20% of pregnant women are affected. The investigator hypothesize that the Aerolase laser treatment could not only enhance the efficacy of the topical depigmenting agents but also by reducing the vascular component decrease the intensity of the relapses.
All patients applied to the entire face the cosmetic depigmenting agent Mela B3 (La Roche Posay) cream twice daily for 3 months. One session of laser on one side of the face (randomly assigned for each patient for the duration of the study) will be performed every other week for 12 weeks for a total of 6 sessions. All the patients will apply the entire face a sunscreen of sun protection factor 50 with high UVA protection (UV Mune 400; La Roche Posay) during the entire study duration.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Nice, Alpes-Maritimes, 06200, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Women of childbearing potential (WOCBP) must have a negative urine pregnancy test result at baseline.
WOCBP are defined as women who are biologically capable of becoming pregnant, including women who are using contraceptives or whose sexual partners are either sterile or using contraceptives.
Women of non-childbearing potential (WONCBP) do not require a urine pregnancy test and must meet at least one of the following criteria:
Exclusion criteria
One session of laser on one side of the face (randomly assigned for each patient for the duration of the study) will be performed every other week for 12 weeks for a total of 6 sessions. All the patients will apply the entire face a sunscreen of sun protection factor 50 with high UVA protection (UV Mune 400; La Roche Posay) during the entire study duration.
Time frame: at 24 weeks
Evaluation of hemi modified hemi mMASI at week 24 for each laser-treated and not laser-treated areas separately. The score was 0-24.
Time frame: at week 12
The patient global assessment is a score graded from 0 (clear); 1 (marked improvement); 2 (moderate improvement); 3 (slight improvement); 4 (no improvement); 5 (worse)
Centre Hospitalier Universitaire de Nice
Other
Treatment and Prevention of Melasma Relapses by Using 1064nm 650 Microsecond Laser: a Prospective Randomized Intra-individual Study
Acronym: Melasma650
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07667972
Hyperpigmentation, Lichen Planus Pigmentosus
Changsha, Hunan, China
View Trial DetailsNCT07036302
Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation
Taubaté, São Paulo, Brazil
View Trial DetailsNCT07034560
Disease Attributes, Hyperpigmentation
Bangkok, Thailand
View Trial DetailsNCT03456674
Hyperpigmentation, Melanosis
New York, United States
View Trial Details